- Home
- STSS vs CDT Comparison
STSS vs CDT Comparison
Compare STSS & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- CDT
- Stock Information
- Founded
- STSS 2017
- CDT 2019
- Country
- STSS United States
- CDT United States
- Employees
- STSS N/A
- CDT N/A
- Industry
- STSS Medical/Dental Instruments
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- CDT Health Care
- Exchange
- STSS Nasdaq
- CDT Nasdaq
- Market Cap
- STSS 5.1M
- CDT 4.6M
- IPO Year
- STSS 2022
- CDT N/A
- Fundamental
- Price
- STSS $7.36
- CDT $1.68
- Analyst Decision
- STSS
- CDT
- Analyst Count
- STSS 0
- CDT 0
- Target Price
- STSS N/A
- CDT N/A
- AVG Volume (30 Days)
- STSS 90.2K
- CDT 81.6K
- Earning Date
- STSS 08-13-2025
- CDT 08-14-2025
- Dividend Yield
- STSS N/A
- CDT N/A
- EPS Growth
- STSS N/A
- CDT N/A
- EPS
- STSS N/A
- CDT N/A
- Revenue
- STSS $222,722.00
- CDT N/A
- Revenue This Year
- STSS N/A
- CDT N/A
- Revenue Next Year
- STSS N/A
- CDT N/A
- P/E Ratio
- STSS N/A
- CDT N/A
- Revenue Growth
- STSS N/A
- CDT N/A
- 52 Week Low
- STSS $3.36
- CDT $1.47
- 52 Week High
- STSS $2,145.00
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- STSS 67.00
- CDT 38.23
- Support Level
- STSS $4.54
- CDT $1.47
- Resistance Level
- STSS $5.95
- CDT $1.85
- Average True Range (ATR)
- STSS 0.74
- CDT 0.11
- MACD
- STSS 0.18
- CDT 0.02
- Stochastic Oscillator
- STSS 96.92
- CDT 48.84
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.